GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms.
СтатьяПоддержка NIH: внешняя программаНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Geng Xiangrong, Wang Chenguang, Gao Xin, Chowdhury Pinki, Weiss Jonathan, Villegas José A, Saed Badeia, Perera Thilini, Hu Ying, Reneau John, Sverdlov Maria, Wolfe Ashley, Brown Noah, Harms Paul, Bailey Nathanael G, Inamdar Kedar, Hristov Alexandra C, Tejasvi Trilokraj, Montes Jaime, Barrionuevo Carlos, Taxa Luis, Casavilca Sandro, de Pádua Covas Lage J Luís Alberto, Culler Hebert Fabrício, Pereira Juliana, Runge John S, Qin Tingting, Tsoi Lam C, Hong Hanna S, Zhang Li, Lyssiotis Costas A, Ohe Rintaro, Toubai Tomomi, Zevallos-Morales Alejandro, Murga-Zamalloa Carlos, Wilcox Ryan A
Аннотация
Neoplasms originating from thymic T-cell progenitors and post-thymic mature T-cell subsets account for a minority of lymphoproliferative neoplasms. These T-cell derived neoplasms, while molecularly and genetically heterogeneous, exploit transcription factors and signaling pathways that are critically important in normal T-cell biology, including those implicated in antigen-, costimulatory-, and cytokine-receptor signaling. The transcription factor GATA-3 regulates the growth and proliferation of both immature and mature T cells and has recently been implicated in T-cell neoplasms, including the most common mature T-cell lymphoma observed in much of the Western world. Here we show that GATA-3 is a proto-oncogene across the spectrum of T-cell neoplasms, including those derived from T-cell progenitors and their mature progeny, and further define the transcriptional programs that are GATA-3 dependent, which include therapeutically targetable gene products. The discovery that p300-dependent acetylation regulates GATA-3 mediated transcription by attenuating DNA binding has novel therapeutic implications. As most patients afflicted with GATA-3 driven T-cell neoplasms will succumb to their disease within a few years of diagnosis, these findings suggest opportunities to improve outcomes for these patients.